Program
apatinib
Also written as “Apatinib”, “Rivoceranib” and “Apatinib Mesylate”.
Its studies are mostly in Stomach Neoplasms · Ovarian Neoplasms · Neoplasms · Carcinoma, Hepatocellular · Carcinoma, Non-Small-Cell Lung, led by 8 companies.
Drug pageApatinib: every studyMany companies study it; this page follows only the 47 they lead. All 428 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicineits history only | 344 open or running | phase 3since Jan 13, 2012 | Aug 30, 2010 | none ahead |
| Elevar Therapeuticsits history only | 70 open or running | phase 3since Jan 24, 2017 | Dec 18, 2011 | none ahead |
| Bukwang Pharmaceutical | 10 open or running | phase 1since Feb 26, 2016 | Feb 26, 2016 | none ahead |
| GrandPharma (China)its history only | 11 open or running | phase 2since Aug 13, 2025 | Aug 13, 2025 | Dec 30, 2027phase 2 · NCT07334483 |
| Guangzhou Virotech Pharmaceuticalits history only | 11 open or running | phase 3since May 8, 2026 | May 8, 2026 | Dec 31, 2028phase 3 · NCT07589244 |
| Hansoh Pharmaceutical Groupits history only | 11 open or running | phase 1since Jan 7, 2025 | Jan 7, 2025 | none ahead |
| HRYZ Biotechits history only | 11 open or running | early phase 1since Aug 26, 2019 | Aug 26, 2019 | none ahead |
| Qilu Pharmaceuticalits history only | 10 open or running | phase 2since Aug 14, 2017 | Aug 14, 2017 | none ahead |
Also a collaborator on its studies: Bukwang Pharmaceutical.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Bukwang Pharmaceutical only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 26, 2016First study: phase 1 study in Stomach NeoplasmsFirst studyNCT02711969 · 6 enrolled · Korea, Republic of
TargetBeta
“Vascular endothelial growth factor receptor 2 inhibitor”ChEMBL 37, by rule
Other programs on KDR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| lenvatinibrule | Eisai | phase 4 | 81 |
| nintedanibrule | Boehringer Ingelheim | phase 4 | 76 |
| regorafenibrule | Bayer | phase 4 | 40 |
| cabozantinibrule | Exelixis | phase 4 | 36 |
| Ramucirumabrule | Eli Lilly | phase 3 | 58 |
| Axitinibrule | Pfizer | phase 3 | 45 |
| anlotinibrule | Sino Biopharmaceutical | phase 3 | 40 |
| vorolanibrule | Betta Pharmaceuticals | phase 3 | 24 |
| zanzalintinibrule | Exelixis | phase 3 | 17 |
| chiauranibrule | Chipscreen Biosciences | phase 3 | 15 |
| Aurora B/VEGFR/FGFR Inhibitor AL8326rule | advenchen-laboratories-nanjing-ltd | phase 3 | 8 |
| AXL/FLT3/VEGFR2 Inhibitor KC1036rule | beijing-konruns-pharmaceutical-co-ltd | phase 3 | 7 |
Studies
The one study Bukwang Pharmaceutical leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02711969Stomach Neoplasms · Korea, Republic of | 1 | Completed | Nov 2016 | 6 |
How it is read
Names in the registry
- “Apatinib”, 13 entries
- “Rivoceranib”, 5 entries
- “Apatinib Mesylate”, 5 entries
- “apatinib”, 3 entries
- “Fluzoparib+Apatinib”, 2 entries
Conditions, from the studies’ own filings
- Stomach Neoplasms, 8 studies
- Ovarian Neoplasms, 6 studies
- Neoplasms, 6 studies
- Carcinoma, Hepatocellular, 5 studies
- Carcinoma, Non-Small-Cell Lung, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.